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Summary. A utility-based Bayesian population finding (BaPoFi) method was proposed
by Morita and Mu¨ller (2017, Biometrics, 1355-1365) to analyze data from a randomized
clinical trial with the aim of identifying good predictive baseline covariates for optimizing
the target population for a future study. The approach casts the population finding process
as a formal decision problem together with a flexible probability model using a random forest
to define a regression mean function. BaPoFi is constructed to handle a single continuous
or binary outcome variable. In this paper, we develop BaPoFi-TTE as an extension of the
earlier approach for clinically important cases of time-to-event (TTE) data with censoring,
and also accounting for a toxicity outcome. We model the association of TTE data with
baseline covariates using a semi-parametric failure time model with a Po´lya tree prior for
an unknown error term and a random forest for a flexible regression mean function. We
define a utility function that addresses a trade-off between efficacy and toxicity as one of
the important clinical considerations for population finding. We examine the operating
characteristics of the proposed method in extensive simulation studies. For illustration, we
apply the proposed method to data from a randomized oncology clinical trial. Concerns in a
preliminary analysis of the same data based on a parametric model motivated the proposed
more general approach.
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1 Introduction
We consider finding sensitive subpopulations for a new treatment based on data of time-
to-event (TTE) efficacy and binary toxicity outcomes in a randomized clinical trial (RCT).
Such approaches are needed, for example, for oncology RCTs that usually evaluate clinical
benefit for patients using TTE outcomes, such as progression-free survival (PFS) and/or
overall survival (OS) as the primary endpoint(s), and also account for toxicity. Investigators
are interested in identifying proper predictive baseline covariates including clinical charac-
teristics and biomarkers of patients to optimize the target population for further treatment
development, and for treatment individualization. The importance of examining predictive
covariates for efficacy and toxicity of a new treatment in a clinical development has been
extensively discussed, among others, by Renfro et al. (2016) and Ondra et al. (2016), etc.
We approach the problem as a Bayesian decision problem. Methodologically, we separate
the construction of the statistical inference model to fit the data, and a description of the
decision, including possible actions and preferences, building on Sivaganesan et al. (2017)
and Morita and Mu¨ller (2017), who propose a utility-based Bayesian population finding
(BaPoFi) method that casts the population finding process as a formal decision problem.
The approach is valid with any sufficiently flexible data model, including Bayesian additive
regression trees (BART) (Chipman et al., 2010, Hill, 2011), multivariate adaptive regression
splines (MARS) (Friedman, 1991), classification and regression trees (CART) (Chipman et
al., 1998), or Gaussian processes (Rasmussen and Williams, 2006). BaPoFi uses BART to
evaluate enhanced treatment effects based on a continuous or binary outcome in patient
subpopulations defined by baseline covariates in an RCT. However, BaPoFi does not work
well for TTE data with censoring. The utility function embedded in BaPoFi evaluates effect
sizes for efficacy, population sizes, and numbers of covariates that are needed to describe
subpopulations, but does not account for safety aspects of treatments.
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In this paper, we propose BaPoFi-TTE as a generalization of BaPoFi for TTE outcomes
and introduce explicit efficacy-toxicity trade-offs to provide a practically useful method for
population finding in the clinical development of a new treatment. To implement such
inference we model both, efficacy and toxicity outcomes, and define the notion of a minimum
clinically meaningful difference (MCMD) in efficacy that is explicitly allowed to vary as a
function of toxicity. Another important feature of the proposed approach is the use of a semi-
parametric Bayesian accelerated failure time (AFT) model with a random forest implemented
in BART as a regression mean function, thereby avoiding restrictive parametric assumptions.
For the same reason, for the unknown residual distribution in the AFT model, we assume
a Po´lya tree prior (Hanson, 2006). An interesting alternative model for similar data is the
BART for TTE probit model for distinct event and censoring times developed by Sparapani
et al. (2016). We use a second instance of BART to model a binary toxicity outcome. This
allows us to introduce efficacy-toxicity trade-offs in the utility function.
There is a substantial literature on methods for patient subpopulation finding with en-
hanced treatment effects. Foster et al. (2011) developed a tree-based algorithm to evaluate
enhanced treatment effects in patient subgroups. Lipkovich et al. (2011) used a recursive
partitioning method to identify patient subgroups with different responses to a treatment.
Schnell et al. (2016) developed a Bayesian credible subgroups method to identify a benefiting
subgroup for a treatment. Jones et al. (2011) give a good review of Bayesian approaches to
subgroup analysis. For decision making related to the study design, Simon and Simon (2018)
proposed a framework for group-sequential adaptive enrichment clinical trials using Bayesian
methods with similar modeling features. Xu et al. (2018) proposed an adaptive approach for
a master protocol clinical trial design using a non-parametric Bayesian model and a utility
function for adaptive allocation and subgroup finding, similar to the utility introduced in
the upcoming discussion. Graf et al. (2015) discuss utility functions to evaluate a benefit
2
risk balance of a treatment in adaptive study designs for subpopulation analysis.
The rest of this paper is organized as follows. In Section 2, we provide the motivating
example. Section 3 presents our proposed approach to finding a sensitive subpopulation as
a decision problem. We introduce a probability model to summarize TTE data in Section
4, and briefly describe the posterior computations in Section 5. In Section 6, we conduct
extensive simulation studies to examine the operating characteristics of the proposed method.
We present results for the motivating study in Section 7, and close with a brief discussion in
Section 8.
2 Motivating example
We analyze data from an oncology randomized clinical trial to find a sensitive subpopulation
for a new therapy. To evaluate sensitive patient subpopulations, clinical papers usually report
extensively so-called subgroup analyses. However, carrying out subgroup analyses with a
large number of candidate covariates gives rise to multiplicity issues due to multiple testing,
and clinical concerns related to the difficulty and complexity in interpreting many between-
treatment-arm comparisons. Such concerns are exacerbated when clinical investigators are
interested in even higher order interaction effects, e.g., between treatment and multiple
covariates.
The proposed approach is motivated by an analysis in Twelves et al. (2016) who carried
out data analysis for OS data from a randomized phase III clinical trial in patients with
locally advanced or metastatic breast cancer (Kaufman et al., 2015). They examined the
influence of baseline patient clinical characteristics on OS. In this trial, 544 and 546 (in
total, 1090) patients received experimental and control treatments, respectively. The study
evaluated OS and PFS as co-primary endpoints. Although a statistically significant difference
in OS was not observed between the two treatments, Kaplan-Meier curves comparing the
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two arms suggested an improvement in OS with the experimental treatment. For safety
evaluation, a noticeable difference in grade 4 hematologic toxicities was reported.
This motivates us to consider a formal subgroup analysis, to search for a benefiting
subpopulation of patients, allowing for an efficacy-toxicity tradeoff. We will report details of
the analysis and results later. In short, the proposed method finds triple negative status as
an important baseline covariate to define the benefiting subpopulation, together with several
other covariates. We will formally describe how the size of the reported subpopulation varies
with the efficacy and toxicity trade-off and the tuning parameters in the utility function.
3 Population finding
Our approach is based on casting inference for population finding as a formal decision prob-
lem. The basic components of a decision-theoretic setup include an action space A of possible
decisions a ∈ A, a probability model p(y,µ) for data y and parameters µ, and a utility func-
tion u(a,µ,y). For the moment we do not need any details of the probability model, and
defer the discussion of a specific model for later, in Section 4. Data may include observed
and future data. We will use y˜ to separately indicate future data, when needed. A util-
ity function u(·) quantifies relative preferences for hypothetical future outcomes (y˜) and
assumed parameter values (µ) under alternative decisions a, given observed data (y). It
can be argued that a rational decision maker should choose an action in A to maximize u
in expectation (Robert, 2007). The expectation is with respect to p(·), conditioning on all
observed data, and marginalizing over all parameters and future data. We will use U(a) to
denote expected utility.
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3.1 Notation
We consider an RCT comparing a TTE outcome, e.g., PFS and OS time, between control (C)
and experimental therapy (N) arms with a total sample size of n patients. Let Ti denote the
event time for patient i. Introducing an event indicator γi, let T
o
i denote either the observed
event time or a (right) censoring time, that is, γi = 1 if T
o
i = Ti and γi = 0 if T
o
i < Ti.
Denoting yi = log(Ti) and y
o
i = log(T
o
i ), let (y
o,γ) =
(
(yo1, γ1), . . . , (y
o
n, γn)
)
denote TTE
data for all n patients. In addition, let y tox = (y tox1 , . . . , y
tox
n ), where y
tox
i = 1 refers to a
toxicity event for patient i. Let z = (z1, . . . , zn) denote treatment indicators with zi = 0 for
arm C and zi = 1 for arm N , and let xi = (xi1, . . . , xip) and X = (x1, . . . ,xn) denote patient
baseline covariates. Throughout, x, z, y without i index denotes data for a generic patient. In
summary, D = (z,X,yo,γ,y tox) denotes all data observed in n patients in the clinical trial.
Let µ and µ tox denote parameters that index the sampling model for the TTE and toxicity
outcomes, respectively, given treatment assignment and covariates. In addition, we introduce
a nonparametric prior model for the residual distribution G in the TTE sampling model,
with the prior involving an additional variance parameter σ2 (details later). We separately
analyze TTE and toxicity outcomes, thus separately analyzing DTTE = (z,X,yo,γ) and
Dtox = (z,X,y tox), as is usually done in RCTs.
Introducing additional notation, log(Ti) = y
unobs
i = y
o
i + κi for censored cases (γi = 0),
let yunobs and κ denote the vectors of yunobsi and κi for censored cases, respectively, and
let yobs denote the vector of observed yoi for uncensored cases (γi = 1). The observed
data (yo,γ) together with κ define the complete data y = (yobs,yunobs). These imply a
joint posterior probability model p(µ, σ2,κ | DTTE) and a posterior predictive distribution
ppp
(
y˜n+1 | zn+1,xn+1,DTTE
)
for a predicted outcome y˜n+1 of a future patient i= n+1. If it is
judged clinically relevant to account for toxicity in conjunction with efficacy, we additionally
evaluate a posterior predictive distribution ppp
(
y˜ toxn+1 | zn+1,xn+1,Dtox
)
of a future toxicity
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observation, y˜ toxn+1, which is derived using a posterior probability model p(µ
tox |Dtox). Note
the notation ppp(·) for the two predictive distributions. In all the above computations, we
assume a priori independent µ, σ2, and µ tox.
3.2 Subgroups
Our approach includes a characterization of subpopulations on the basis of discretized and
categorical covariates, xj, j = 1, . . . , p. For continuous covariates, taking typical sample
sizes of clinical trials into account, we consider trichotomizing each covariate. Let Q33j and
Q67j denote the 33% and 67% quantiles of xj. For categorical covariates with more than
three categories, we consider merging categories to fewer, clinically meaningful categories.
Let {M1, . . . ,Md} generically denote the two (d = 2) or three (d = 3) categories of a
dichotomized or trichotomized categorical covariate. We use subsets Wj ⊂ {M1, . . . ,Md} to
describe subgroups of patients.
We report a subgroup of most benefiting patients based on trichotomized (or dichotomized)
covariate values Wj as follows
a =
(
J,W
)
, (1)
where J ⊆ {1, . . . , p} indicates the covariates that characterize the subgroup, and W ={
Wj, j ∈ J
}
indicates the levels of those covariates. We write {i : xi ∈ a} as short for
{i : xi,j ∈ Wj for j ∈ J}. Let SG(a) = {i : xi ∈ a} denote patients within the subgroup
selected by a. For example, we may report that the patient subgroup a =
(
j,Wj = {M2,M3}
)
is sensitive to treatment N and xj is the predictive covariate of the subgroup. In addition,
we introduce two more special cases, a = “null” for reporting that treatments N and C
show same efficacy and toxicity effects in any populations, and a = “all” for reporting that
treatment N is more effective than treatment C, equally so for the entire population of
patients.
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In the present study, we consider only sensitive subgroups that are defined by one or two
predictive covariates. We introduce this restriction because three or more predictors may not
be interpretable or practically useful, and also to keep the computational effort reasonable.
Thus, we restrict to J = {j} or J = {j, k}. For the one-covariate cases, J = {j}, we
evaluate all the six subsets: Wj = {M1}, {M2}, {M3}, {M1,M2}, {M2,M3}, and {M1,M3}
with respect to every covariate xj, j = 1, . . . , p. For the two-covariate cases, J = {j, k}, we
construct all the possible combinations of one from the six subsets of xj and one from those
of xk, resulting in rectangular subgroups or L-shaped subgroups. A rectangular subgroup
is constructed as {x : xi,j ∈ Wj and xi,k ∈ Wk}. L-shaped subgroups are an ad-hoc way
of slightly generalizing the rectangular subgroups to {x : xi,j ∈ Wj or xi,k ∈ Wk} (by
allowing the union instead of the intersection). The two restrictions on the action space
A by discretizing covariates and limiting the number of predictive covariates, contribute to
make the proposed method practically useful, as will be discussed later in the simulation
and application sections.
3.3 Utility function
To examine heterogeneous treatment effects depending on patient covariates, we use a po-
tential outcomes framework, and introduce potential outcomes
{
yn+1(C), yn+1(N)
}
and{
y toxn+1(C), y
tox
n+1(N)
}
. respectively. In actual data, of course only one element of the pair
is observed (Rubin, 1978; Hill, 2011). For a TTE outcome, letting S(t) denote the sur-
vival probability at time t, we evaluate the differences in survival probabilities, S(τ | z =
1,x) − S(τ | z = 0,x). The threshold τ is chosen to be a meaningful time horizon for the
condition and treatment under consideration. For a binary toxicity outcome, we evaluate
the differences in toxicity probabilities between treatment arms.
Recall thatDTTE andDtox denote all observed efficacy and toxicity data. In preparation
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for the upcoming construction of a utility function, we define the predictive conditional
treatment effect (PCTE) for a future patient i=n+ 1. Let x˜ = xn+1, y˜ = yn+1, y˜
tox = y toxn+1,
and z˜ = zn+1. We define
PCTETTE(x˜,DTTE) = S(τ | z˜ = 1, x˜,DTTE)− S(τ | z˜ = 0, x˜,DTTE), (2)
where the probabilities are calculated with respect to the posterior predictive distribution
ppp(y˜ | z˜, x˜,DTTE). Similarly, PCTE tox(x˜,Dtox) = E
{
y˜ tox(N)− y˜ tox(C) | x˜,Dtox}, where
the expectation is with respect to the posterior predictive distribution ppp(y˜
tox | z˜, x˜,Dtox).
Finally, we define the predictive average treatment effect (PATE) for the TTE outcome in a
selected subgroup by averaging PCTETTE(x˜,DTTE) over x˜ in subgroup a, as
PATETTESS (a) =
1
|SG(a)| ·
∑
i∈SG(a)
PCTETTE(xi,D
TTE). (3)
The sum is over all observed patients in SG(a), implying the use of the empirical distribution
to average over patients with covariates in subgroup a. We similarly define PATE toxSS (a) for
the toxicity outcome.
Next, we define a minimum clinically meaningful difference in efficacy δ (MCMD). We
allow δ to vary as a function of y tox, i.e., δ {y tox(N), y tox(C)}, and define an average MCMD
over a subgroup as
δa =
∑
i∈SG(a)
E
(
δ
{
y˜ tox(N), y˜ tox(C) | x˜ = xi,Dtox
})
. (4)
Here, the expectation is with respect to ppp(y˜
tox | x˜, z˜,Dtox). As a specific function δ(·)
we use δ = δ0 + δ1
{
y tox(N)− y tox(C)}, where δ0 has the interpretation of an MCMD under
no difference in toxicity between N and C and δ1 is a slope. In this case, δa reduces to
δa = δ0 + δ1PATE
tox
SS (a).
Finally, using PATE and δa, we then propose a utility function to formalize preferences
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in terms of efficacy and toxicity across possible actions of subgroup reporting (a).
U(a) =

[
PATETTESS (a)− δa
] |SG(a)+1|ν
(|J |+1)ζ if a 6= null
u0 if a = null
(5)
where the positive constants (ν, ζ, u0) are tuning parameters. Later, in Section 6.2, we
will show how (ν, ζ) can be used to achieve desired frequentist operating characteristics. In
addition, u0 specifies the utility for the action a = null, and is a convenient tuning parameter
to achieve a desired type I error rate. Since PATE and δa already include marginalization
w.r.t. y˜, the function (5) is already an expected utility. Writing (5) as a product of three
factors,
U(a) = E
{
m
[
a,
{
y˜(N), y˜(C)
}
,
{
y˜ tox(N), y˜ tox(C)
}]} · g(|SG(a)|) · h(|J |),
highlights how the utility function includes a preference for larger benefit sizes (m), larger
subpopulation size (g), and parsimonious description (h).
Finally, some more comments on the MCMD. One possible way to determine δ(·) is
elicitation from physicians. We consider here, as an example, using a linear function
δ
{
y tox(N), y tox(C)
}
= δ0 + δ1
{
y tox(N)− y tox(C)}, (6)
as described above. To specify the intercept δ0 and the slope δ1, one may solicit (1) an
MCMD value in efficacy when assuming no difference in toxicity between N and C; (2) an
upper bound of unacceptable difference in toxicity probabilities between N and C at which
δ(·) takes the maximum value of expected difference in efficacy between treatment arms,
e.g., 0.5 when using the difference in survival probabilities to compare N and C. Then, we
use the MCMD value obtained in (1) to specify δ0, and divide (the maximum efficacy value
− the MCMD value) by the upper bound value of unacceptable difference to specify δ1. For
example, the MCMD value = 0.2 and the toxicity upper bound value = 0.2 give δ0 = 0.2
and δ1 = (0.5− 0.2) / 0.2 = 1.5.
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Under the outlined framework, we determine an optimal rule a∗ known as the Bayes rule,
which is formally described as
a∗ = arg max
a
U(a). (7)
In addition to a∗, we also recommend to report slightly suboptimal choices. For example, the
top 5 instead of only the formal Bayes rule a∗ in (7). This mitigates undesirable sensitivity
with respect to technical details in the utility function (5) and the assumed probability model
(related to technical convenience rather than expert judgment).
4 Probability model
We model the TTE outcome with an AFT model, yi = η(zi,xi,µ) + ui, i = 1, . . . , n,
where η(·) denotes a mean function (“linear term” in a traditional AFT model), µ indexes
the model for η(·) (details below), and ui is a residual. Since the earlier decision of the
selection of the subgroup report did not rely on any details of the probability model, we are
free to use any model to fit the data. For an optimal fit of the data without restriction to a
parametric family, we propose a non-parametric Bayesian model. We use a Bayesian random
forest model, BART (Chipman et al., 2010; Hill, 2011), for the mean function and assume
a non-parametric Po´lya tree (PT) prior (Lavine, 1992) for the residual distribution G(ui).
The nonparametric priors avoid strict parametric assumptions. Let ηBT (zi,xi,µ) denote
the BART mean function, and let G ∼ PT(A, G0) denote the PT prior for the residual
distribution G. In summary,
yi = ηBT (zi,xi,µ) + ui, i = 1, . . . , n,
ui ∼ G, i.i.d., G ∼ PT(A, G0),
(8)
subject to G(−∞, 0) = 0.5. The first set of hyperparameters, A, defines the probability
of nested sequences of partitions of a sample space via beta distributions. The second
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hyperparameter, G0, defines centering of the random probabilty measure G. We assume
G0 = N(0, σ
2).
We use BART as a prior for the mean function mainly because of the availability of a very
computation-efficient implementation as public domain R package. BART consists of two
parts, a sum-of-trees model (random forest) and a regularization prior on the parameters
of the model. The BART model allows to naturally incorporate main effects as well as
interactions. Let µ generically denote all BART parameters including in particular terminal
node parameters that represent main and interaction effects. For the residual distribution,
we choose a PT prior over other alternative non-parametric priors because it naturally lends
itself to restricting to zero median as needed to keep the interpretation as residual distribution
(Lavine, 1992). In addition, a PT prior allows a closed form expression of the marginal
distribution of residuals (u1, . . . , un) in (8), that is,
Gmg(u1, . . . , un | σ2) ≡ p(u1, . . . , un) =
∫ n∏
i=1
G(ui)dp(G),
(Mu¨ller et al., 2015). The conditioning on σ2 in Gmg arises because we assume N(0, σ
2) for
G0 in the PT prior. Semi-parametric AFT models with PT priors have been used before in
Hanson (2006) and Walker and Mallick (1999). See Ibrahim et al. (2001) for a review.
For the probability model for a binary toxicity outcome, refer to Morita and Mu¨ller
(2017).
5 Prediction using MCMC
We use MCMC posterior simulation (Gilks et al., 1996) to generate posterior Monte Carlo
samples of µ and σ2. Recall that yunobsi = y
o
i + κi for censored cases (γi = 0), that is,
κi together with the censoring time implicitly defines y
unobs
i . Also, let y = (y
obs,yunobs)
denote the complete data, and let ηBT (z,X,µ) =
(
ηBT (zi,xi,µ); i = 1, . . . , n
)
. In sum-
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mary, the MCMC proceeds in three steps: Step 1, updating µ to obtain new ηBT (z,X,µ);
Step 2, updating σ2; and Step 3, obtaining yunobs by imputing κ for censored cases. In
other words, we iterate over sampling from the full conditional posterior distributions p(µ |
z,X,yobs,yunobs, σ2), p(σ2 | z,X,yobs,yunobs,µ), and p(κ | z,X,yo,γ,µ, σ2). In Step 3, we
implicitely update yunobsi . The generated posterior Monte Carlo sample allows us to evaluate
posterior predictive distributions ppp(y˜ | x˜, z˜,DTTE) as Monte Carlo averages. The scheme
integrates the BART method (Chipman et al., 2010) and the setup of Walker and Mallick
(1999, Sec. 3).
We add some more implementation details for Steps 1 through 2. We use Metropolis-
Hastings (M-H) type transition probabilities in Step 1, using the BART package (R Package
BayesTree; Core Team: R, 2014) to generate a proposal, and an appropriate M-H acceptance
probability to account for the fact that we replace the normal residual distribution that is
assumed in the BART software by a PT random probability measure. To see the right M-H
acceptance probability consider (8), with G marginalized out analytically, i.e., (u1, . . . , un) ∼
Gmg(u1, . . . , un | σ2). The conditional posterior for µ is therefore determined by the BART
prior p(µ) and the likelihood Gmg(u | σ2), i.e.,
p(µ | z,X,y, σ2) ∝ p(µ)Gmg(u | σ2), with u = (u1, . . . , un), ui = yi − ηBT (zi,xi,µ).
The definition of ui makes Gmg(u | σ2) implicitly a function of µ. On the other hand, the
BART software assumes the same prior p(µ), but normal residuals ui ∼ N(0, σ2). Let q(u |
µ, σ2) denote the normal distribution of the residuals ui under the BART model. BART uses
the conditional posterior q(µ | z,X,y, σ2) ∝ p(µ) q(u | µ, σ2). We use q(µ | z,X,y, σ2) as
the proposal distribution for an M-H transition probability that updates µ (and therefore
implicitly ηBT (zi,xi,µ)). Importantly note that the above two posteriors differ only by the
likelihood. More specifically, Gmg(u | σ2) includes a factor that is identical to the normal
likelihood q(u | µ, σ2). This is due to the use of G0 = N(0, σ2) as the centering distribution
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in the PT prior. In the end, the remaining factors in Gmg(·) are left as the M-H acceptance
probability.
In Step 2, the conditional posterior for σ2 is determined by (8), again with G marginalized
out analytically, as
p(σ2 | z,X,y,µ) ∝ p(σ2)Gmg(u | σ2).
We assume a scaled inverse gamma prior p(σ2). To implement a M-H algorithm to update
σ2, we use the proposal posterior distribution q(σ2 | z,X,y,µ) ∝ p(σ2) q(y | µ, z,X, σ2),
again with the conjugate normal likelihood q(y | µ, z,X, σ2) as in Step 1, implying an
inverse-gamma posterior q(σ2 | . . .). Similarly to Step 1, the acceptance ratio in the M-H
transition probability in Step 2 simplifies greatly.
For a binary toxicity outcome, refer to Morita and Mu¨ller (2017) for details.
6 Simulation study design
To evaluate the operating characteristics of the proposed method, BaPoFi-TTE, we sim-
ulated 1,000 hypothetical realizations of the RCTs with a balanced design with equal 1:1
allocation to the two treatment arms (new treatment N vs. control C). We performed
the simulation study with ten covariates (p = 10) and a total sample size of n = 400 un-
der seventeen assumed true scenarios. For the TTE data, we randomly selected censored
cases to induce 10% censoring. Additional simulations were carried out with sample sizes
n = 100, 200, 300, 400, and 500, and a censoring proportion 50%, still with p = 10.
We will later discuss frequentist summaries under repeat simulation. These summaries,
e.g., true positive rate, require the notion of a “true subpopulation” under the simulation
truth. However, the simulation truth only defines true sampling models for the TTE and
toxicity outcomes denoted by p 0TTE(y | z,xTTE,θ 0,TTE) and p0tox(y tox | z,xtox,θ0,tox), re-
spectively (see below for details). Importantly, the specifications of p 0TTE(·) and p0tox(·) do not
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include any notion of true subgroups. Instead we define a true subgroup as follows. Let U0(a)
denote the utility (5) under the simulation truth, that is, we replace the calculation in (2)
and the expectation in PCTE tox(x˜,Dtox) by expectations under p0TTE(y | z,xTTE,θ0,TTE)
and p0tox(y
tox | z,xtox,θ0,tox). Under each simulation scenario, we computed U0(a) for all
subgroups. The subgroup with the highest U0(a) value is the “true subpopulation” for the
subgroup report.
6.1 Data generation
We first simulate TTE outcomes yi under assumed simulation truths p
0
TTE(y | z,xTTE,θ0,TTE)
using eleven different scenarios for p0TTE with no difference in toxicity between treatment
arms N and C (we added a superscript on xTTE, to allow for different sets of baseline
covariates for TTE and toxicity models). This defines scenarios 0 and E1 through E10.
Next, we include two scenarios (T1 and T2) for the toxicity outcome, with simulation truth
p0tox(y
tox | z,xtox,θ0,tox). We then combine the two toxicity scenarios with three out of the
TTE scenarios to assume six scenarios for the efficacy-toxicity trade-off evaluation (scenarios
E1*T1 through E4*T2, below). For both, the TTE and toxicity outcomes, we assumed that
all covariates were continuous, and generated xij independently from a normal N(0,1). We
briefly summarize the data generation below.
Scenario 0 is an overall null case (H0) assuming no difference in both, the TTE and
toxicity outcomes between arms N and C. Scenario E1 is an overall alternative case (H1)
with an overall treatment effect of arm N . As shown in Figure 1, Scenarios E2 (1-L), E3
(1-M), and E4 (1-S) are scenarios with one predictive covariate (x1) and large (67%, E2),
moderate (50%, E3), and small (33%, E4) subpopulations. Here percent are the subgroup
size as % of the entire population. Scenarios E5 (2-M), E6 (2-S) and E7 (2-S) are scenarios
with two predictive covariates (x1, x2) and moderate (45%, E5), small (25%, E6), and
14
small (22%, E7) subpopulations. Scenarios E8 (1-S) and E9 (1-M) assume that an inward
subset and distant subsets are sensitive, respectively. Scenario E10 (2-MLs) is a case with
two predictive covariates (x1, x2) and an L-shaped sensitive subpopulation of moderate size
(55%). For toxicity, Scenarios T1 (1-S) and T2 (1-L) are scenarios for small (33%, T1) and
large (67%, T2) subpopulations. Both are defined with one predictive covariate (x6) which
is different from those for efficacy (x1, x2).
Combining scenarios E1, E2, and E4 with T1 and T2, we assume Scenarios E1∗T1 (1-
L) and E1∗T2 (1-S) with one predictive covariate (x6) and assume Scenarios E2∗T1 (2-M),
E2∗T2 (2-S), E4∗T1 (2-S), E4∗T2 (2-VS: very small, 11%) with two predictive covariates
(x1, x6).
For the TTE outcome, we use the following log-linear model with a linear term gTTE(·)
to generate data for patient i,
yi = gTTE(zi,x
TTE
i ,θ
0,TTE) + ei, ei ∼ N(0, s2), (9)
where θ0,TTE = (β0,TTE0 ,β
0,TTE, γ0,TTE) with β0,TTE0 for the overall treatment effect of arm N ,
β0,TTE for the covariates, and γ0,TTE for the interaction effect between treatment and predic-
tive covariate(s). That is, we use gTTE(zi,x
TTE
i ,θ
0,TTE) = β0,TTE0 zi + hTTE(x
TTE
i ,β
0,TTE) +
γ0,TTE zi I(·) and hTTE(xTTEi ,β0,TTE) = 0.1x1,i + 0.05x2,i − 0.1x3,i − 0.1x4,i + 0.05x5,i −
0.05x1,ix3,i. Here, I(·) denotes an indicator function to specify the sensitive subpopulation
for each scenario explained above. For example, Scenarios E2 and E5 use I(x1,i ≥ Q331 ) and
I(x1,i ≥ Q671 ∪ x2,i ≥ Q332 ), respectively. As described in Section 3.2, Qqj indicates a q%
quantile value of xj. We set the residual variance s
2=12.
To generate a binary toxicity outcome for patient i under the toxicity scenarios T1 and T2,
we use a logistic model for p(y tox = 1 | xtox,θtox) with the linear term gtox(zi,xtoxi ,θ0,tox) =
htox(x
tox
i ,β
0,tox) + γ0,tox zi I(x6,i ≤ Q6) and use htox(xtoxi ,β0,tox) = 0.05x6,i − 0.1x7,i −
0.1x8,i + 0.05x9,i + 0.1x10,i − 0.05x6,ix8,i. That is, we assume no overall difference in the
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probability of toxicity between arms N and C (to simplify the efficacy-toxicity combination
scenarios).
Each scenario above implies survival probabilities S(τ) and overall (marginal) toxicity
probabilities (Pr(tox)), for arms N and C in the sensitive and non-sensitive subpopulations.
We use τ = 90 (days) for all the efficacy scenarios. The implied values of the differences
in S(τ) and in Pr(tox) between arms N and C in the sensitive subpopulations used for in
the simulation study are shown in Figures 2a and 2b. For the TTE outcome, the simulation
truth implies S(τ)=0.20 in arm C for all efficacy scenarios. For Scenarios E2 through E10,
the simulation truth implies S(τ)=0.30 in arm N, that is, S(τ) of arm N is 10% higher than
that of arm C in the non-sensitive subpopulation. For the toxicity outcome, the simulation
truth implies Pr(tox)=0.10 in arm C and no difference in Pr(tox) is assumed between arms
in the non-sensitive subpopulation for the two scenarios.
6.2 Frequentist operating characteristics
Recall that the BaPoFi method reports the top 5 subgroups with the five highest utilities
U(a). Letting the superscript c denote the absence of the specific report in the top 5 sub-
groups, we evaluated several errors, as frequentist rates. We use the following six error rates
Pr(a | b), where a (ac) indicates that a decision is (is not) among the top 5 decisions and b
behind the conditioning bar refers to a simulation truth (with a slight abuse of the condi-
tioning bar). Here Pr(·) denotes frequentist probabilities under repeat simulation. Thus, for
example, Pr(null | H0) is the proportion of trials under the simulation truth H0 in which
the top 5 reports contain a = null. We report six summaries that can be conveniently
summarized by true decision rate (TDR) and false decision rate (FDR). TDR includes true
negative rate (TNR) = Pr(null | H0), true positive rate (TPR) = Pr(all | H1), and true
subgroup rate (TSR) = Pr(a | Ha). Under a given simulation truth only one of these three
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rates applies. FDR includes false negative rate (FNR) = Pr(null and ac | Ha) under Ha or
Pr(null and all c | H1) under H1, false positive rate (FPR) = Pr(all and ac | Ha), and false
subgroup rate (FSR) = 1 − Pr(a or null or all | Ha) or 1 − Pr(null or all | H1). FDR is
the sum of FNR, FSR and, in the case of a simulation truth Ha, FPR. In other words, under
Ha and H1, FSR is the proportion of trials which report a false subgroup. Note that type I
error (T1E) is included as 1−TNR = Pr(null c | H0).
We use the tuning parameters ν, ζ, u0 in the utility function (5) to achieve desired levels
of the described frequentist operating characteristics. We adjust u0 to achieve desired type-I
error rate under a null simulation truth. In our implementation, we varied ν and ζ on a
grid between 0.10 and 0.50 (in increments of 0.05). After determining (ν, ζ) = (0.25, 0.15)
under p = 10 and n = 400, we set u0 = −0.304. When using the approach for data from
a real clinical study, one may specify the tuning parameters, based on results of the repeat
simulation using the actual numbers of covariates and patients and the summaries of efficacy
and toxicity outcomes.
6.3 Simulation results
Figure 2a summarizes simulation results with four operating characteristics for n = 400 and
p = 10 under the ten efficacy clinical scenarios. Figure 2b shows those under the six efficacy-
toxicity trade-off scenarios. Under Scenario 0 (null scenario: H0), the TDR was 0.95, that
is, the TIE was controlled at 0.05.
Under Scenarios E1-E4, we find high TDRs under 40% of the difference in survival prob-
abilities, S(τ), between N and S, while moderate TDRs under the difference of 30%. Taking
that the difference of 40% in S(τ) indicates a substantial efficacy of treatment N into ac-
count, the BaPoFi-TTE performs sufficiently well under a regular sample size (n=400) for
randomized clinical trials.
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Under Scenarios E5-E7 with two predictive covariates, BaPoFi-TTE maintains accept-
able rates. Similarly to the above four scenarios, performance of BaPoFi-TTE improves
as the difference in S(τ) increases. It should be noted that the BaPoFi-TTE performs
well regardless of the subpopulation size. These results further suggest higher flexibility of
BaPoFi-TTE in subpopulation finding.
Under Scenarios E8 and E9 with the challenging inward and distant subsets and under
Scenario E10 with the more challenging L-shaped simulation truth, BaPoFi-TTE continues
to work reasonably well as the difference between treatment arms increases to 50%.
As shown in Figure 2b, under the clinical scenarios combining the three efficacy and two
toxicity scenarios, the BaPoFi-TTE imbedding a utility function accounting for the efficacy-
toxicity trade-off shows good performance in population finding. Overall, the TDR values
increase as the differences between treatment arms in efficacy and toxicity outcomes become
larger in the respective subgroups, as expected. However, several points should be noted as
follows.
Under Scenario E1∗T1 where treatment N has a high efficacy in the entire population but
gives a high toxicity occurrence in a small patient population, the BaPoFi-TTE frequently
fails to include (the true) Ha among the top five subgroup reports and wrongly includes
H1 as the high FPR values indicate. This undesirable performance (FPR = 0.52) is also
observed under Scenario E1∗T2 with a large toxic subpopulation when the efficacy difference
is 0.40 and the toxicity difference is 0.25. Under the other scenarios, in cases the patient
subpopulation to be reported has a small size, the BaPoFi-TTE performs reasonably well if
sufficient contrasts are observed between the efficacy and toxicity outcomes. These findings
suggest the importance of pre-analysis discussion with physicians about which toxicities
should be accounted and how to define a function δ(·) and its parameters (i.e., δ0 and δ1)
for the efficacy-toxicity trade-off in a utility function.
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Figure 3 summarizes TDR (=TSR) values under Scenarios 3, 5, and 7 with p = 10 and
sample sizes n = 100, 200, 300, 400, and 500 and censoring proportions = 10 and 50%. Over-
all, the BaPoFi-TTE performs better as the sample sizes increases for the three scenarios,
as expected. This exploratory investigation suggests that when the number of covariates
of interests is moderate, say around p = 10, a sample size of larger than or equal to 400
may be required to provide around 70% TDR to find a small to moderate size (say 25 to
50% of n) subpopulation defined by two predictive covariates, while 200 may be enough for
one-covariate cases, unless the censoring proportion is not so high.
The acceptance rates of µ and σ2 in Steps 1 and 2 in the MCMC computations were on
average 0.191 and 0.574, respectively, under Scenario 2. Similar values were observed under
the other scenarios.
7 Application to a phase III trial
We applied the proposed BaPoFi-TTE method to the study that we already briefly intro-
duced earlier, in Section 2. In this phase III trial, 544 and 546 (in total, 1090) patients
received treatment N and treatment C, respectively (Kaufman et al., 2015). In this applica-
tion, we analyzed OS as the efficacy TTE outcome. For the toxicity evaluation, we selected
the occurrence of grade 4 hematologic toxicities, that is, either of neutropenia, leukopenia,
anemia, and febrile neutropenia, because a noticeable difference in the grade 4 hematologic
toxicities was noted.
We compared the differences in survival probabilities at τ = 720 days between arms N
and C. We additionally carried out the analysis using two alternative time horizons with
τ = 690 and τ = 750 to evaluate the sensitivity of the analysis to the time-cutpoints. For the
efficacy analysis, we set δ0 = 0.2 and δ1 = 0.0 in the MCMD (6), implying a fixed MCMD
value of δ0. We evaluate the efficacy-toxicity trade-offs using δ1 = 1.5 and δ0 = 0.2 (com-
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pare the brief example after (6)). For each of the efficacy and toxicity analyses, we selected
candidate covariates from the available baseline patient covariates. Noting that predictive
and risk factors need not be the same for efficacy and toxicity outcomes, we allowed for
partially different sets of covariates for the efficacy and toxicity analyses. We used ‘age’,
‘body mass index (BMI)’, ‘number of prior chemotherapy regimens for advanced/metastatic
disease [0/1/2≤]’, ‘disease progression within 60 days after the last dose of chemotherapy
[yes/no]’, ‘triple negative (TN) [yes/no]’, and ‘race [white/non-white]’ in common for the effi-
cacy and toxicity analyses. We include ‘site of disease [visceral/non-visceral only]’, ‘adjuvant
therapy [yes/no]’, ‘neo-adjuvant therapy [yes/no]’ only in the efficacy analysis, while contain-
ing ‘performance status [0/1/2≤]’ only in the toxicity analysis. Patients whose statuses of
the human epidermal growth factor receptor 2 (HER2), estrogen receptor, and progesterone
receptor are all negative are classified into ‘TN [yes]’.
From the total 1090 patients, we excluded 13 due to missing data in the covariates of
‘BMI’ or ‘site of disease’. We then analyzed data from 1077 patients (N : 538, C: 539). We
implement BaPoFi-TTE using the p = 8 covariates. We set u0 = −0.327 to control T1E at
0.05. In addition, we determined to use (ν, ζ) = (0.20, 0.15) based on the earlier reported
simulation study under n=400 and taking the increase in the total sample size to n=1077
into account. As an ad-hoc sensitivity analysis, we carried out alternative analysis using
(ν, ζ)=(0.30,0.15).
Figure 4 shows the top 5 subgroup reports, in descending order from the left, using the
same format as in Figure 1. The first row shows the result from the efficacy analysis using
the OS outcome only. Based on the frequency of the clinical covariates that appear in the
top 5, we note TN as the most probable sensitive covariate for treatment N . Four additional
covariates, ‘site of disease [visceral]’, ‘disease progression within 60 days [yes]’, ‘race [white]’,
and ‘age’ are promising candidates to identify more focused sensitive subpopulations for
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treatment N in combination with ‘TN [yes]’. The second row shows results from the efficacy-
toxicity trade-off analysis. The results of this analysis give us deeper insights for evaluating
possible patient subpopulations being more suitable for treatment N . First, the subgroup
specified by the single covariate TN went down below the top 5. Then, the analysis identified
a new covariate ‘BMI’ with different cutoffs (66.7% and 33% points) to define the first and
fourth best subgroups. Comparing the occurrences of grade 4 hematology toxicity between
treatment arms with respect to the BMI subgroups, the difference in the toxicity occurrence
between arms increased as the BMI level decreased. In summary, we report that the subgroup
of triple negative patients with higher baseline BMI level is a more desirable subpopulation
for treatment N when taking the efficacy-toxicity balance into account.
As shown in the bottom two rows, the analysis with larger ν=0.30 tends to rate larger
subpopulations more favorably compared to the first and second rows. Recall that ν repre-
sents preference for a larger population size. In addition, the sensitivity analyses with the
two additional cutoff timepoints τ (=690 and 750) overall supported the above findings.
8 Discussion
The proposed BaPoFi-TTE method casts the population finding problem as a formal Bayesian
decision problem, that is, we separate the construction of the assumed statistical inference
model and a description of the possible actions and preferences. The BaPoFi-TTE method
evaluates efficacy-toxicity trade-offs and uses a semi-parametric failure time model with a
random forest method, BART, and a Po´lya tree prior to fit TTE data. However, any other
flexible sampling models could be used. A decision theoretic approach often depends on
the arbitrary definition and choice of a utility function and its design parameters. Thus,
we report the top 5 subgroups rather than the optimal subgroup under controlling the type
I error rate to mitigate undesirable sensitivity to technical details in the utility function.
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When clinical investigators need more focused recommendations, it may be vital to take
advantage of as much prior medical knowledge as possible.
Some more limitations remain. The described approach does not deal with missing (not
available) covariates as it may occur in real clinical data analyses. But using a model-based
approach, it is easy to extend the current method to impute missing data. Finally, deter-
mining optimal cutoff points especially for continuous covariates is an important remaining
issue.
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Figure Legends
Figure 1. Clinical scenarios for the simulation study. The new treatment provides a higher
efficacy in the shadow area than the rest, that is, the area shows the interaction effect
between treatment and covariates (x1, x2), under each of Scenarios E2 to E10. Scenario 0
is the overall null case (H0), while Scenario E1 is overall alternative case (H1). The new
treatment gives a higher toxicity due to covariate x6 in the shadow area than the rest under
each of Scenarios T1 and T2. Combinations of E1, E2, and E4 with T1 and T2 define six
scenarios for the efficacy-toxicity trade-off evaluation.
Figures 2a and 2b. Simulation results of the BaPoFi-TTE method (2a for efficacy; 2b for
efficacy-toxicity) with (n=) 400 patients and (p=) 10 covariates, summarized in terms of
true decision rate (TDR) and false decision rates (FDR). TDR unifies true negative rate
(TNR) under Scenario 0, true positive rate (TPR) under Scenario E1, and true subgroup
rate (TSR) under the others. FDR includes false negative rate (FNR), false positive rate
(FPR), and false subgroup rate (FSR). The scenarios are characterized by the number of
predictive covariates (0, 1, 2), the size (L: large, M: moderate, S: small, VS: very small)
and shape (rectangular, distant (Dt), L-shaped (Ls)) of sensitive subpopulation, and the
differences in S(τ=90) and Pr(tox) between N and C in the sensitive subpopulation, denoted
by D-S(τ)S and D-Pr(tox)S, respectively.
Figure 3. True decision rates (= true subgroup rates) for the BaPoFi-TTE with the number
of covariates p = 10, censoring proportions = 10% and 50%, and for the total sample size
values n = 100, 200, 300, 400, 500, under Scenarios 3, 5, and 7. Differences in S(τ=90)
between N and C in the sensitive subpopulation are all 40%.
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Figure 4. Application of the BaPoFi-TTE method to a phase III clinical trial, reporting
the top 5 subgroups with (ν, ζ) = (0.20,0.15) and (0.30,0.15) from the efficacy and efficacy-
toxicity trade-off analyses. % values in the boxes indicate the subgroup sizes of the selected
subpopulations. “TN” denotes “triple negative”, “PD in 60 days” means “disease progression
within 60 days after the last dose of chemotherapy”, and “BMI” denotes “body mass index”.
“Y” in the parenthesis denotes “yes”, and Q33j and Q
67
j are the 33% and 67% point cutoff
values, respectively.
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